In-House Developed Multiple Myeloma Drug Leads the Way for Sanofi

Paris-based Sanofi announced positive results from its pivotal Phase III trial of isatuximab in patients with relapsed/refractory multiple myeloma. The drug, in combination with Celgene’s Pomalyst/Imnovid (pomalidomide) and low-dose dexamethasone, met the primary endpoint of prolonging progression-free survival compared to patients receiving the standard of care, which is pomalidomide and low-dose dexamethasone alone. Sanofi indicates they will present the results at an upcoming medical conference and plan to submit to regulators later his year.
“We are excited by these results, which represent significant progress in our ambition to extend the lives of multiple myeloma patients,” stated John Reed, head of Research and Development at Sanofi. “We look forward to engaging with regulatory authorities with the goal of bringing this potential new treatment to patients as quickly as possible.”